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Ten-year neonatal hepatitis B 
vaccination program, the Netherlands, 
19824992: protective efficacy and 
long-term immunogenicity 
R. de1 Canho*, P.M. Grosheide*, J.A. Mazel_t, R.A. Heijtink$, W.C.J. Hops, 
L.J. Gerards 11, G.C. de Gastll, W.P.F. Fetter’, J. Zwijneberg” and 
S.W. Schalm*h 
From 1982 to 1989, 705 infants born to HBsAg-positive mothers entered the Dutch 
neonatal hepatitis B vaccination program and received passive-active hepatitis B 
immunization in three randomized controlled trials testing variations in time of starting 
active vaccination, dose and type of vaccine, and number of hepatitis B immuno- 
globulin (HBIg) injections. A meta-analysis of individual patient data of the three 
randomized trials was per$ormed to determine which independent host and vaccination 
related factors influence protective efJicacy and long-term immunogenic& and to 
assess whether hepatitis B vaccination concomitant with standard DKTP vaccination 
provides optimal protection. Statistical methodology included multivariate logistic 
regression analysis. Eight infants (1.1%) all born to HBeAg-positive mothers, became 
HBsAg carriers within the first year of life. The protective efficacy rate (PER) of 
passive-active immunization at 12 months follow-up was 92% for the total group of 
children from 114 HBeAg-positive mothers with no significant diflerences between 
children starting active immunization at birth or at 3 months of age, between infants 
starting at 3 months of age receiving one or two doses of HBIg or between those 
receiving plasma derived or recombinant vaccine. The only factor that affected the 
PER significantly was the level of maternal HBV DNA; PER was 100% if maternal 
HBV DNA was < 15Opg ml-’ and 68% for HBV DNA levels > 15Opg ml-‘. After 5 
years of follow-up, the group that started active immunization at birth had significantly 
more infants with loss of seroprotection (anti-HBs levels ~10 IU Ill, 15%) than the 
corresponding group starting at 3 months of age (anti-HBs ~10 IU ll’, 2%). One of 
3.5 children with loss of seroprotection at 2 years became a HBsAg cam’er in the fifth 
year of follow-up. This meta-analysis shows that the protective ejjicacy of passive- 
active hepatitis B vaccination is mainly influenced by material HBV DNA levels, and 
independent of the time of starting active vaccination at birth or at 3 months of age; 
long-term immunity was enhanced by starting active vaccination concomitant with 
DKTP vaccination. These findings allow incorporation of hepatitis B vaccine into the 
standard infant immunization programs for countries with a passive-active immuniza- 
tion strategy for the control of hepatitis B. Additional measures are needed to protect 
neonates of highly viremic women. 0 1997 Elsevier Science Ltd. 
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When hepatitis B vaccine was licensed in the Nether- 
lands in 1982, a program was started to screen mothers 
for HBsAg positivity and to immunize their offspring. 
In the first randomized trial a passive-active immuniz- 
ation schedule starting at birth was compared with a 
schedule with active immunization starting at 3 months 
of age, concomitant with diphtheria-tetanus-pertussis 
and pohomyelitis (DTPP) vaccination. The authors 
hypothesized that efficacy of delayed active immuniza- 
tion would be similar, but long-term immunogenicity 
superior to immunization starting at birth. Such a 
result would allow incorporation of active hepatitis B 
immunization in the standard infant immunization 
program, which was thought to be advantageous with 
respect to logistics and costs. Our preliminary results 
supported this hypothesis’,‘. In 1984 a second random- 
ized trial was started to compare the short- and long- 
term immunogenicity of the standard vaccine dose with 
a pediatric dose. With the introduction of recombinant 
vaccine in 1987, a third randomized trial was 
performed to confirm the efficacy of delayed vaccina- 
tion with the recombinant vaccine; this trial also 
allowed testing the need for supplementary hepatitis B 
immunoglobulins (HBIg) at the start of delayed active 
immunization3. 
Our recent finding4, also observed by others’-7, that 
vaccination failure is also related to high maternal 
HBV DNA levels made it necessary to re-evaluate the 
effects of the components of the various schedules: 
time of starting active immunization, types and doses 
of vaccine and HBIg used, in relation to maternal 
HBV DNA levels. 
This final report of the Dutch program for preven- 
tion of perinatal hepatitis B describes the protective 
efficacy and long-term immunogenicity of passive- 
active hepatitis B immunization over a period of 10 
years. 
SUBJECTS AND METHODS 
Hepatitis B screening 
The study was started in July 1982 in three large city 
hospitals in Rotterdam and Utrecht and one large rural 
area, Twente-Gelderse Achterhoek. Blood samples 
obtained from all pregnant women at their first visit to 
the prenatal clinic of the participating centers were 
tested for the presence of HBsAg. If HBsAg positivity 
was confirmed, randomization to one of the immuniza- 
tion schedules took place after informed consent was 
Table 1 Immunization schedules of study groups 
obtained from the mother. In the two participating 
hospitals in Rotterdam, the HBsAg status of expectant 
mothers was checked soon after arrival in the delivery 
room. Whenever prenatal HBsAg test results were 
missing, blood was obtained and tested the next 
morning with a rapid hemagglutination HBsAg test. If 
the rapid HBsAg test was positive, the mother was 
asked for informed consent and the baby was random- 
ized and included in the immunization trial. All 
pregnant HBsAg-positive women were also tested for 
the presence of HBeAg. In December 1992, maternal 
HBV DNA levels were quantified retrospectively in the 
available stored serum samples positive for HBeAg. 
Subjects and immunization schedules 
From July 1982 to March 1984, 238 eligible babies 
were randomly allocated to one of the two initial 
plasma vaccine immunization schedules (Tahlu I, 
groups I-II); from April 1984 to December 1987. 257 
babies entered the plasma vaccine immunogenicity 
study (Table I, groups III-IV); from January 1988 to 
October 1989, another 210 eligible babies were 
allocated to one of the two recombinant vaccine 
immunization schedules (Table I, groups V-VI). 
All infants received HBlg (200-300 IU, Central 
Laboratory of the Netherlands Red Cross Blood Trans- 
fusion Service, Amsterdam) i.m. within 2 h of birth by 
the physician or midwife in charge of the delivery. For 
active immunization, infants were referred to a pedia- 
trician. Infants received plasma vaccine (10 and 5 /cg 
HBvax, Merck Sharp & Dohme, West Point, USA) or 
recombinant vaccine (20 /lg Engerix-B, SmithKline 
Beecham, Rixensart, Belgium). Nine infants (one in 
group II, three in group III and five in group IV) with 
an anti-HBs level I 10 IU 1 ’ at 12 months of age and 
a negative test for HBsAg received an additional 
course of plasma vaccine or recombinant vaccine in 
their second year of life. 
Serological assays and laboratory methods 
Blood samples were taken from the infants at birth 
(cord blood) and in groups I and II at months 3, 6, I I, 
12 and then yearly until 9 years of age; in groups III 
and IV at months 3, 6, 12 and then yearly until 5 years 
of age; in groups V and VI at months 3. 4, 6, 11, 12 
and at 2 years of age. All serum samples were tested 
for anti-HBs and anti-HBc; HBsAg w$s assayed in all 
samples with anti-HBs below lot) IU 1 . 
No. of infants HEUS” Vaccine Schedule 
Total Evaluated for Evaluated for Months/ 
Group 
Months after 
Entry period (mother HSeAg+) immunogenicity efficacy” monhs dose after birth Type/dose birth 
I 1932-19846 117 (38) 110 (35) 103 o/200 10 I (37) 8  21 42 plasmad 0, 1.2.11 09
1984-19876 
7 jig 
105 Ill (41) 0,3/209.125 133 (3) plasma 10 3, 4, 5, 11 128 (2) /lg 
127 IV (3) O/200 10 1994-1987 124 (4) 0, 179 122 (4) plasma jig 
115 (2) o/200 
V 1998-1989 112 (14) 102 (13) 
plasma 5 jrg 0, 1.6 
O/300 recomb.” 20 
VI 
99 (14) 
1989-1989 93 (17) 
3, 4, 5, 11 
93 Total (17) 
119 
83 (17) 0,3/300,300 recomb. 20 2 3 705 18) /lg 3, 4. 11 5. 664 06) 
631 (114) 
“Hepatitis 6 immunoglobulin, Central f&oratory of the Dutch Red Cross Blood Transfusion Service, The Netherlands; “infants of HBeAg 
positive mothers entered in group I and II until December 1987; %etween parentheses number of infants with HBeAg positive mothers; 
“H&ax, Merck Sharp & Dohme, Westpoint. USA; “Engerix-8. SmithKline Gee&am Biologicals. Riiensart, Belgium 
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HBsAg, HBeAg, anti-HBc and anti-HBs were 
assessed using a commercial radioimmunoassay kit 
(Abbott Laboratories, Chicago, IL, USA). HBV DNA 
was measured quantitatively by a solution hybridization 
assay (HBV DNA, Abbott Laboratories). 
Definition of HBV infection 
A HBV carrier state was defined as being HBsAg 
positive for more than 6 months. Transient HBV infec- 
tion was characterized by the presence of HBsAg in 
serum for less than 6 months. Inapparent HBV infec- 
tion was defined as anti-HBc positivity without HBsAg 
on two or more occasions after 12 months. 
Statistical analysis 
Available data were analysed according to the inten- 
tion-to-treat principle. Separate per-protocol analysis, 
i.e. analysis of data of children who received vaccina- 
tions according to protocol, was also performed. The 
results of these analyses did not differ significantly. 
Therefore, the authors report on the protective efficacy 
using outcomes of the intention-to-treat analysis; the 
results on the immunogenicity are reported using the 
outcomes of the per-protocol analysis. 
For analysis of factors affecting the protective 
efficacy rate, logistic regression analysis8 was applied. 
Confidence limits for odds ratio were calculated using 
the statistical software package ‘STATXACT’. Differ- 
ences in percentages were analysed by xz test or 
Fisher’s exact test in case of small numbers. Contin- 
uous variables were analysed by the two-sample 
Wilcoxon rank-sum test. The limit for significance was 
set to 0.05 (two-sided). In case of evaluations at various 
timepoints, the limit of significance was set according 
to Bonferroni’s principle to allow for the multiplicity of 
statistical tests. Geometric mean titers (GMT) were 
calculated only for those infants who had anti-HBs 
2101u1-‘. 
Ethics 
The study was approved by the local Medical Ethics 
Committee of the participating centers. 
RESULTS 
Follow-up 
From July 1982 until October 1989, 705 infants of 
HBsAg-positive mothers were randomized into three 
controlled trials. Sixteen infants were withdrawn after 
informed consent but before vaccination, 12 infants 
received at least one vaccination, but no serum sample 
was available after month 0. In total, 677 infants 
received full courses of passive-active immunization 
according to six schedules (Table I). Thirteen infants 
received vaccinations but not according to protocol 
(one in group I, four in group II, one in group III, one 
in group IV, three in group V and three in group VI). 
Thus, 664 infants received passive-active immunization 
according to protocol. Serum samples were available 
from 590 children at 1 year of follow-up, 546 after 2 
years, 262 after 5 years and 126 after 8 years. Incom- 
plete data from these children were primarily due to 
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secondary refusal of the parents, related to the 
frequency of blood sampling (up to ten samples) 
during the study, and migration. 
Protective efficacy of perinatal HBV immunization 
At month 12, HBsAg positivity was found in tight of 
590 infants. Of 33 infants no strum sample was avail- 
able at month 12 but they wcrc HBsAg ncgativc thcrc- 
after, so the assumption was made that thcrc was no 
HBsAg positivity at month 12. From tight of the I3 
infants who received a vaccination schcdulc not 
according to protocol, strum samples wcrc availahlc 
and found to bc HBsAg ncgativc at month 12 or thcrc- 
after. Of 631 (i.e. 590+3+8) infants analyscd, tight 
(1.3%) were found to be HBsAg-positive during the 
first year of lift. All HBsAg-positive children wcrc born 
to HBeAg-positive mothers. 
One infant of a HBcAg-ncgativc mother bccamc 
HBsAg positive at the age of 5 years (&p-c I); it had 
a peak anti-HBs lcvcl bctwccn 10 and IO0 IU I ’ after 
vaccination, but was anti-HBs ncgativc from 2 years 
onwards. This child and all infants found to bc HBsAg- 
positive in the first year hccamc hepatitis B carriers. 
Inapparcnt HBV infection (anti-HBc positivity with 
negative HBsAg tests on two or more occasions after 
month 12) was observed in tight infants, all born to 
HBeAg-positive mothers. 
At month 12, the protcctivc cfticacy rate (PER) of 
passive-active immunization for the I I4 infants of 
HBsAg- and HBcAg-positive mothers was YO%. 
(Table 2). No significant diffcrcnccs wcrc found 
between the PER for infants starting active vaccination 
at birth and those starting at 3 months; bctwccn infants 
starting at 3 months and rccciving one or two doses of 
HBIg and hctwcen infants rccciving plasma vaccine or 
recombinant vaccine. 
In 72 of the 114 HBcAg-positive mothers, residual 
frozen serum was available for quantitative HBV DNA 
assessment in lY92. Tuhk 3 shows the relation of 
maternal HBV DNA levels and the number of infants 
who became HBV carriers. The PER at month 12 for 
the two groups with HBV DNA lcvcls < I50 pg ml ’ 
were 100% and significantly higher than the PER 
(68%) for the group with maternal HBV DNA lcvcls 
2 150 pg ml ’ (P = 0.009). 
Follow-up (years) 
Figure 1 Chronic HBV infection after 5 years of follow-up in one 
infant, born to an HBeAg-negative mother, despite a response to 
neonatal passive-active hepatitis B immunization (group II) 
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Table 2 Protective efficacy of passive-active hepatitis B immunization, at month 12 in infants of HBeAg-positive mothers, according to 
different vaccination schedules 
PER llmonthsa (“/, 
No. of infants Expected % of infants with HBV 
infections without prophylaxis 
HBsAg HBsAg positivity 
Group Total positive (%) difference in % (95% CI) 90% 670Xb 
Vaccine starting month 0 42 3 (7.1) 0.2 (-9.5, +9.9) 92 89 
Vaccine starting month 3 72 5 (6.9) 92 90 
HBlg month 0 56 4 (7.1) 0.2 (-9.2,+9.2) 92 89 
HBlg months 0,3 58 4 (6.9) 92 90 
Plasma vaccine 83 6 (7,2) 0.7 (-9.6,+11.0) 92 89 
Recombinant vaccine 31 2 (6.5) 93 90 
Total 114 8 (7.0) 92 90 
aPER = (expected number of HBV infections without immunoprophylaxis minus measured number of HBV infections in immunization group) 
divided by the expected number of HBV infections without immunoprophylaxis) x 100%; ?he expected number of HBV infections without 
immunoprophylaxis for infants from HBeAg positive mothers is usually estimated at 90%“~“, however, PER was also calculated for 67% 
expected HBV infections without immunoprophylaxis, in view of the finding that one-third of infants of HBeAg-positive mothers had HBV 
DNA < 5 pg ml ’ and are therefore unlikely to transmit hepatitis B to their infants’ 
Figure 2 shows the maternal HBV DNA levels for 
HBV infected infants and non-infected infants. The 
median maternal HBV DNA level of the HBV carrier 
infants and that of the inapparently infected infants 
were ten times higher ( ~350 pg ml-‘) than the median 
maternal HBV DNA level (31 pg ml ‘) of the infants 
without HBV infection (P = 0.001 and 0.03, 
respectively). 
When data on time of starting active vaccination, 
number of doses of HBIg and type of vaccine were 
analysed by multivariate logistic regression, no signifi- 
cant differences were found (odds ratio confidence 
intervals were from 0.001 to > 10). When the analysis 
was expanded with HBV DNA data, both the factor 
HBV DNA as well as HBV DNA > 150 pg mll’ were 
significantly associated with the PER. 
Long-term immunogenicity 
Assuming a minimal risk for hepatitis B infection in 
vaccinees with anti-HBs levels > 10 IU I-‘, and a 
potential risk with anti-HBs levels < 10 IU ll’, the 
authors calculated the percentages of infants with anti- 
HBs < 10 IU ll’ in the different immunization groups 
(Figure 3). At the age of 5 years, the group that started 
at 3 months of age with plasma vaccine (group II) had 
a significantly lower percentage (2%, 95% CI O-6%) of 
children with anti-HBs < 10 IU 1 ’ than group I (14%, 
95% CI 6-23%) that started immunization at birth 
(Fisher’s exact test, P = 0.02). The percentage of 
infants with anti-HBs < 10 IU 1. ’ in group II never 
exceeded 5% during the 5 year follow-up, whereas the 
corresponding percentage in the other immunization 
groups increased to > 15% during follow-up. 
Table 4 shows the GMT of anti-HBs (anti-HBs 
210 IU I-‘) in the different immunization groups 
during follow-up. GMT of group II (10 ,ug plasma 
vaccine administration from 3 months of age onwards) 
was approximately double that of group I (starting at 
birth with 10 lug plasma vaccine). In the groups with 
different dosages of vaccine, the GMT at month 12 in 
group III with three doses of 10 pg plasma vaccine 
administered from birth onwards, was approximately 
double that of group IV, which received the same 
schedule but only 5 pg of plasma vaccine. However, 
this difference was not significant after 36 months of 
follow-up. Comparison of GMT values of groups given 
plasma vaccine or recombinant vaccine from 3 months 
onwards showed that the group receiving plasma 
vaccine (group II) had an approximately one and half 
times higher GMT than the corresponding group 
receiving recombinant vaccine (group VI) (P<O.OOl at 
all times measured). 
DISCUSSION. 
In this meta-analysis of individual patient data of three 
randomized controlled trials, the PER against hepatitis 
B infection for infants of HBeAg-positive carrier 
mothers was 90% at 12 months of age; for infants of 
HBeAg-negative mothers it was 100%. These rates are 
comparable to those found in other passive-active 
immunization studies, with either plasma-derived or 
recombinant vaccine9-‘3. During follow-up beyond 1 
Table 3 Protective efficacy rate (PER) of passive-active hepatitis B immunization at month 12 according to maternal HBV DNA levels 
No. of infants 
PER 12 rnO”fhS 
HBV DNA (pg ml ‘) Total HBsAg positive(%) 90% P-value 
16 24 0 (0) n.a.a 
7-150 24 0 (0) 100 
>r 150 24 7 (29) 68 0.009* 
*Fisher’s exact test between number of HBsAg-positive infants in group with HBV DNA > 150 pg ml-’ and groups with HBV DNA of 7-l 50 
and <6 pg ml-‘; owing to small numbers of infants, the exact 95% CI of the ratio of the odds of HBsAg positivity in the group of infants 
with HBV DNA <I 150 pg ml-’ (odds O/48) versus the corresponding odds (7/24) in the group with HBV DNA > 150 pg ml-’ was calculated 
(this 95% CI ranged from 0 to 0.22); anot applicable, in view of the finding that infants of HBeAg-positive mothers with HBV DNA <5 pg ml-’ 
are unlikely to transmit hepatitis B to their infants’ 
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year, extending to 9 years, one vaccinated infant of an 
HBeAg-negative mother became positive for HBsAg. 
The timing of the initial vaccine injection, the type 
of the vaccine and the number of doses of HBIg had 
no effect on the PERs. These results confirm earlier 
findings. Beasley et al.“. reported that, with HBIg 
I- median J 
0.1 0 
noninfected HBsAg+ anti-HBc+ 
infants infants infants 
Figure 2 Maternal HBV DNA levels of seven chronic HBV 
infected infants, four inapparent HBV infected infants and of 61 
non-infected infants. Cut-off level of HBV DNA assay is 1.7 pg ml -’ 
- plasma IOpg a- group I (0.1.2, I I ) 
plasma lqlg -o- group II (3.4.5.1 I ) 
_ plasma IOpp -0- group Ill (0. I .6) 
plasma 5pg + group IV (0. I .6) 
recomb. 2Oflg -*- group V (X4.5. I I ) - 
- recomb. 2Opg + group VI (X4.5, I I ) 
24 3h 
Months 
Figure 3 Percentages of infants with anti-HBs ~10 IU I. ’ in the 
six immunization groups. Bars indicate standard errors. Resutts at 
2 years are similar for groups starting vaccination at birth or at 3 
months of age. Long-term follow-up suggests excellent persist- 
ence of protective humoral immunity for infants starting vaccina- 
tion at 3 months of age 
coverage at birth, the timing of the start of active 
vaccination appeared to be of no im ortance. A retro- 
spective analysis by Marian et al. ,B suggested lower 
efficacy for those receiving delayed vaccination; this 
finding, however, relates to compliance rather than to 
the biology of immune protection. Stevens et al.‘* 
published results indicating that yeast recombinant 
vaccine was as effective as plasma-derived vaccine in 
preventing hepatitis B virus infection. The authors of 
this study found no evidence of a need for a second 
dose of HBIg in combination with delayed active 
immunization; evidence from other studies for the 
necessity of such action has not been forthcoming. 
In the setting of our program, with the use of 
licensed vaccine and adequate dosage of HBIg, the 
single clinically relevant factor that did influence the 
PER was the level of serum HBV DNA of the mother 
at the time of delivery. PER in groups of infants with 
maternal HBV DNA levels < 150 pg ml- ’ was lOO%, 
but only 68% for the group with a maternal HBV 
DNA level of 2 150 pg ml-~‘. 
To verify the finding that PER is markedly influ- 
enced by maternal HBV DNA levels, the authors 
analysed the protective efficacy rate at 12 months of 
age according to quantified maternal HBV DNA levels 
from the neonatal hepatitis B vaccination program in 
Hong Kong (9 P.N. Lelie, written communication). In 
the Hong Kong study, no persistent HBsAg positivity 
at 12 months was detected in infants with maternal 
HBV DNA <5 pg ml- ‘, irrespective of immunization 
schedule. Infants with maternal HBV DNA between 7 
and 150 pg ml-’ were at risk of hepatitis B infection 
(15-28% HBsAg carrier rate). Infants with maternal 
HBV DNA levels of > 150 pg ml-’ were at high risk of 
hepatitis B; 25-50% of infants became persistent 
HBsAg positive despite immunization. These results 
strongly support the concept that the level of maternal 
HBV DNA is the major factor influencing the PER of 
hepatitis B immunization. 
Recently, hepatitis B ‘escape mutants’, lacking the 
‘a’ epitope on the viral envelope were found in vacci- 
nated infants”. The authors did not observe coexist- 
ence of HBsAg and anti-HBs in seven infants with 
persistent HBsAg. However, additional laboratory 
investigations including in vitro neutralization of 
HBsAg by polyclonal anti-HBs (HBIg, CLB) and 
sequence analysis of the ‘a’ domain revealed one 
arginine 145 variant in three cases that were available 
for investigation. ‘Escape’ mutants may also play a role 
Table 4 GMT anti-HBs (anti-HBs 2 10 IU I-‘) in the six immunization groups during follow-up. Values in parentheses are the 95% CI 
GMT anti-HBs (IU I-‘) 
Group Month 12 Month 24 Month 36 Month 48 Month 60 
I (0,1,2,11; 10 j’g PI.) 8730(6238-l 2217) 737(533-1019) 353(24&502) 207(145-296) 137(92-203) 
II (3,4,5,11; 10 j1g PI.) 15739(11738-21104) 1728(1284-2325) 820(596-l 129) 484(356-231) 331(231-473) 
P-value” 0.023 0.001 0.0006 0.0004 0.0002 
< vsp sp = ‘0.5” 
Ill (0,1,6; 10 pg pl.) 1142(849-1537) 331(245-447) 202(151-271) 138(100-90) 100(70-143) 
IV (0.1.6; 5 pg PI.) 608(438-846) 203(146-283) 163(116-228) 114(78-l 66) 75(52-109) 
P-valueb 0.0012 0.0066 0.19 0.31 0.11 
< vsp sp = ‘0.5 
V (3,4,5,11; 20 cg rec.) 9317(6558-l 3237) 1727(1216-2452) _ _ _ 
VI (3,4,5,11; 20 pg rec.) 9699(6475-14528) 1125(767-1649) _ _ _ 
P-value’ 0.13 0.84 
‘Between groups I and II; ?&ween groups Ill and IV; “between groups V and VI 
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in a low-endemic region like northwestern Europe, but 
the extent of the problem appears limited. 
Long-term immunogenicity was significantly higher 
in the group receiving late active immunization than in 
the group starting directly after birth. At the age of 5 
years, the group with delayed active immunization had 
a significantly lower percentage (2%) of children with 
anti-HBs ~10 IU I-’ than groups in which immuniza- 
tion was started at birth (15-25%). This finding is in 
agreement with others who found an enhancement of 
the immune response if the infant was older at the 
time of the initial injection, probably related to a more 
mature immune system’4.‘“. The implications of these 
findings are at present unclear. If protection against 
hepatitis B infection depends on the degree of 
immunologic priming reflected by the persistence of 
antibody, then a strong argument could be made for 
adoption of schedules that maximize anti-HBs levels. 
In the present study, there was a total follow-up of 186 
person-years in 71 infants with anti-HBs < 10 IU I ‘. 
One infant, born to a HBeAg-negative mother, with an 
initial response between 10 and 100 IU I-’ became 
HBsAg carrier after 4 years of follow-up without 
detectable anti-HBs. In other studies, no HBsAg 
positivity after 5-9 years of follow-up was found for 
infants with initial anti-HBs 2 10 IU 1 ‘, whether the 
infants lost their anti-HBs or not’4,‘“‘x. In long-term 
follow-up studies of immunized adults, no persistent 
HBsAg positivity was detected in persons with an 
initial anti-HBs response > 10 SRU, but transient 
HBsAg positivity and/or anti-HBc positivity was 
detected in this group, < 1% in 100 person-years 
exposed”. At present, until more long-term follow-up 
studies are available, it seems advisable to aim for an 
initial anti-HBs response of 100 IU I- ’ or more for the 
prevention of clinically important forms of hepatitis 
B”‘. 
The confirmation of an old finding that there was 
no effect of the time of starting active immunization 
on PER facilitates the incorporation of hepatitis B 
vaccine into the existing Expanded Programme on 
Immunization (EPI) by allowing active hepatitis B 
vaccination concomitant with DKTP immunization. 
The number of visits can then be reduced as well as the 
number of injections if a multivalent vaccine becomes 
available. 
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